This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.
Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. . ... Together with partner FibroGen, Astellas has submitted a supplemental
Another oral HIF-PHI drug – AstraZeneca and FibroGen’s roxadustat– has already been approved in China for CKD anaemia.Additional competition could come from Akebia, which has a drug in the ... Astellas Pharma meanwhile has rights to roxadustat in
Comes with increased blood pressure warning label. AstraZeneca and FibroGen say they are preparing a US filing of roxadustat for anaemia in chronic kidney disease after reporting cardiovascular outcomes data from ... There is a significant unmet medical
And in another positive development, AZ also announced today that two additional phase 3 trials of its just-approved drug for anaemia in chronic kidney disease patients – roxadustat – backed the efficacy
Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels. ... AZ and FibroGen have rights to roxadustat in the US, China and other world markets, while
Roxadustat works by turning on the body's machinery for producing red blood cells that is usually stimulated by reduced oxygen levels in the blood. ... In addition, use of roxadustat is free of the burden of cold-chain storage and maintaining sterility,
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before Europe and the US,” says Mallon. ... Finally, a data readout for roxadustat is expected by the end of 2018
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
I am energised to join a company with such an innovative pipeline, as well as the first-in-class asset roxadustat, which has the potential to change the treatment paradigm in
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...